Pellegrini, S.; Zamarian, V.; Landi, E.; Cospito, A.; Lombardo, M.T.; Manenti, F.; Citro, A.; Schiavo Lena, M.; Piemonti, L.; Sordi, V.
Treating iPSC-Derived β Cells with an Anti-CD30 Antibody–Drug Conjugate Eliminates the Risk of Teratoma Development upon Transplantation. Int. J. Mol. Sci. 2022, 23, 9699.
https://doi.org/10.3390/ijms23179699
AMA Style
Pellegrini S, Zamarian V, Landi E, Cospito A, Lombardo MT, Manenti F, Citro A, Schiavo Lena M, Piemonti L, Sordi V.
Treating iPSC-Derived β Cells with an Anti-CD30 Antibody–Drug Conjugate Eliminates the Risk of Teratoma Development upon Transplantation. International Journal of Molecular Sciences. 2022; 23(17):9699.
https://doi.org/10.3390/ijms23179699
Chicago/Turabian Style
Pellegrini, Silvia, Valentina Zamarian, Elisa Landi, Alessandro Cospito, Marta Tiffany Lombardo, Fabio Manenti, Antonio Citro, Marco Schiavo Lena, Lorenzo Piemonti, and Valeria Sordi.
2022. "Treating iPSC-Derived β Cells with an Anti-CD30 Antibody–Drug Conjugate Eliminates the Risk of Teratoma Development upon Transplantation" International Journal of Molecular Sciences 23, no. 17: 9699.
https://doi.org/10.3390/ijms23179699
APA Style
Pellegrini, S., Zamarian, V., Landi, E., Cospito, A., Lombardo, M. T., Manenti, F., Citro, A., Schiavo Lena, M., Piemonti, L., & Sordi, V.
(2022). Treating iPSC-Derived β Cells with an Anti-CD30 Antibody–Drug Conjugate Eliminates the Risk of Teratoma Development upon Transplantation. International Journal of Molecular Sciences, 23(17), 9699.
https://doi.org/10.3390/ijms23179699